Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ABBV-969 in metastatic castration-resistant prostate cancer
jRCT2051240092Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ABBV-969 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants with adverse events and Percentage of participants achieving PSA response. Started Aug 2024; status: recruiting.
02
Drugs
ABBV-969
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2051240092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240092.